ClinicalTrials.gg
CompletedNCT04308304DDIUpdated Aug 15, 2024Results posted

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

A Phase 1 interventional study of MK-1942 and Donepezil in Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
47th of 58
27 · median 79
Started
2021
with 1 other
Phase 1
20 of 60
1 open now
Registered
56th of 60
by date
Lead sponsor
3 of 60
Merck Sharp & Dohme LLC

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 47th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2021, is one of 20 in phase 1, and was the 56th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The study investigated the effects on safety and pharmacokinetics (PK) of MK-1942 and donepezil when co-administered to participants with Alzheimer's Disease with mild-to-moderate cognitive impairment stably treated with donepezil. The objectives of this study were to determine if the combination of MK-1942 with donepezil increases the incidence or severity of adverse events (AEs) previously reported for these agents alone, or results in unanticipated AEs in the patient population targeted for MK-1942 treatment. In addition, changes in the PK parameters of either MK-1942 or donepezil as a result of co-administration were assessed.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • Donepezil
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥18 and ≤35 kg/m\^2, inclusive.
  • Is in good health based on medical history, physical examination, vital sign measures and performed prior to randomization.
  • Have a negative urine drug screen prior to randomization.
  • Have a history of cognitive and functional decline with gradual onset and slow progression for at least one year before screening that is either corroborated or well-documented.
  • Be receiving donepezil (maximum dose: ≥10-mg, ≤15-mg) for symptomatic treatment of cognitive impairment associated with Alzheimer's dementia. The dose level must be stable for at least 1 month prior to screening.
  • Have a reliable and competent trial partner/caregiver who has a close relationship with the subject, has face-to-face contact at least three days a week for a minimum of six waking hours a week, and is willing to accompany the participant, if desired, to trial visits. The trial partner/caregiver should understand the nature of the trial and adhere to trial requirements (e.g., dosing, visit schedules, and nature and number of evaluations).
  • use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Male participants must refrain from donating sperm PLUS agree to study guidelines regarding abstinent and/or contraception during the intervention period and for at least an additional 90 days (a spermatogenesis cycle) after the last dose of study intervention:
  • A female participant is eligible to participate if she is a women of nonchildbearing potential by study criteria.

Exclusion criteria

Exclusion Criteria:

  • Is positive for surface antigen, antibodies or (HIV).
  • Is at imminent risk of self-harm, based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale (CSSRS), or of harm to others in the opinion of the investigator.
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pretrial (screening) visit.
  • Has a history of uncontrolled, endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Candidates should not have a history of asthma, , urinary obstructions or gastrointestinal bleeding.
  • Has a history of cancer () exceptions for (1) Adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix or; (2) Other malignancies which have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study.
  • Has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or non-prescription drugs or food.
  • Has evidence of a clinically relevant or unstable psychiatric disorder, based on The (DSM-5) criteria, including schizophrenia or other psychotic disorder, bipolar disorder, or delirium at the time of the pre-study (screening) visit, or has a history of clinically significant psychiatric disorder of the last 5 years.
  • Has participated in another study within 4 weeks (or 5 half-lives, whichever is greater) prior to the pre-study (screening) visit.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Donepezil

    Participants receive Dose Level 1: 8-mg MK-1942 twice daily (BID) x 7 days (7D), Day 1 to Day 7; Dose Level 2: 15-mg MK-1942 BID x 7D, Day 8 to Day 14; Dose Level 3: 30-mg MK-1942 BID x 7D, Day 15 to Day 21; Dose Level 4: ≤50-mg MK-1942 BID x 7D (Provisional Dose Level), Day 22 to Day 28 All participants to receive Donepezil once daily.

    Drug: MK-1942 · Drug: Donepezil

  • Placebo comparator
    Placebo

    Placebo to MK-1942 BID x 21 \[28\] D All participants to receive Donepezil once daily.

    Drug: Donepezil · Drug: Placebo

Interventions

  • MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.

  • Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.

  • DrugPlacebo

    Placebo capsule matched to MK-1942 taken BID by mouth.

06

What researchers measure

Primary outcomes

  1. Number of Participants With ≥1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Day 42

  2. Number of Participants Discontinuing From Study Therapy Due to an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Day 28

  3. Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Findings

    The number of participants with clinically significant 12-lead ECGs is presented. Recordings were made throughout the study, with the participant in a semi-recumbent position having rested in this position for at least 10 minutes beforehand.

    Time frame: Up to Day 28

  4. Number of Participants With Abnormal (Impaired) Results on Targeted Neurological Exams

    The number of participants with abnormal (impaired) results on targeted neurological exams will be presented. The targeted neurological exam contains Modules 1, 2 and 5 of the general examination, focusing on arousal, cranial nerve function, and gait and will be administered several times throughout the treatment period starting on Day 1 up until Day 29. The number of participants with abnormal (impaired) results on targeted neurological exams will be reported. Each exam will be graded as Normal or Impaired with the abnormality described.

    Time frame: Up to 29 days

  5. Number of Participants Who Reported Suicidal Ideation and/or Behavior on Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS)

    The number of participants with suicidality using the C-SSRS is presented. The C-SSR will be used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. C-SSRS assessment will be based upon a clinician's interpretation of the participant's responses to the C-SSRS questions, not by a numbered scale. Suicidal ideation and/or behaviors identified on the C-SSRS may not be considered an adverse event, based on the investigator's judgment. Participants who report at least one occurrence of suicidal behavior or suicidal ideation will be counted as having experienced suicidality. Suicidal behavior includes suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation include a wish to die or active suicidal thought with or without method, intent or plan.

    Time frame: Up to 42 days

  6. Change From Baseline in Heart Rate (HR)

    The mean change from baseline in HR is presented. Change in HR was determined the first day of treatment with a new dose of MK-1942. A negative value indicates a decrease in HR relative to baseline, and a positive value indicates an increase.

    Time frame: Baseline (Day -1) and Days 1, 8, 15, and 22: 2 hours postdose

  7. Change From Baseline in Systolic Blood Pressure (SBP)

    The mean change from baseline in SBP is presented. Change in SBP was determined the first day of treatment with a new dose of MK-1942. Negative values represent a decrease in SBP relative to baseline, and positive values represent an increase.

    Time frame: Baseline (Day -1) and Days 1, 8, 15, and 22: 2 hours postdose

  8. Mean Change From Baseline in Diastolic Blood Pressure (DBP)

    The mean change from baseline in DBP is presented. Change in DBP was determined the first day of treatment with a new dose of MK-1942. Negative values represent a decrease in DBP relative to baseline, and positive values represent an increase.

    Time frame: Baseline (Day -1) and Days 1, 8, 15, and 22: 2 hours postdose

  9. Number of Participants With Abnormal Clinical Chemistry Test Results Reported as Adverse Events

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal chemistry-related AEs is reported.

    Time frame: Up to 42 days

  10. Number of Participants With Abnormal Clinical Hematology Test Results Reported as Adverse Events

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal hematology-related AEs is reported.

    Time frame: Up to 42 days

  11. Number of Participants With Abnormal Urinalysis Results Reported as Adverse Events

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with an abnormal urinalysis results AE is reported.

    Time frame: Up to 42 days

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve (AUC) From Dosing to 12 Hours Postdose (AUC0-12) of MK-1942

    AUC0-12 is reported for the first day of treatment of each MK-1942 dose.

    Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  2. AUC From Dosing to 24 Hours Postdose (AUC0-24) of MK-1942

    AUC0-24 is reported for the first day of treatment of each MK-1942 dose. Due to twice daily dosing, AUC0-24 was calculated as "AUC0-24 = AUC0-12 x 2".

    Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  3. Maximum Plasma Concentration (Cmax) of MK-1942

    Cmax is reported for the first day of treatment of each MK-1942 dose.

    Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  4. Trough Plasma Concentration (Ctrough) of MK-1942

    Ctrough is reported for the first day of treatment of each MK-1942 dose. Data from healthy elderly participants used for statistical analyses are unpublished findings from study MK-1942-004.

    Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  5. Time to Reach Maximum Plasma Concentration (Tmax) of MK-1942

    Tmax is reported for the first day of treatment of each MK-1942 dose.

    Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  6. Apparent Terminal Plasma Half-Life (t½) of MK-1942

    t½ is reported for MK-1942 50 mg.

    Time frame: Day 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  7. Apparent Clearance at Steady-state (CLss/F) of MK-1942

    CLss/F is reported for MK-1942 50 mg.

    Time frame: Day 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  8. Apparent Volume of Distribution at Steady State (Vzss/F) of MK-1942

    Vzss/F is reported for MK-1942 50 mg.

    Time frame: Day 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  9. AUC0-24 of Donepezil

    AUC0-24 is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28). Due to twice daily dosing, AUC0-24 was calculated as "AUC0-12 x 2".

    Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  10. Cmax of Donepezil

    Cmax is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).

    Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  11. Ctrough of Donepezil

    Ctrough is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).

    Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

  12. Tmax of Donepezil

    Tmax is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).

    Time frame: Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose

07

Results

Posted Aug 15, 2024

Participant flow

Male and female adult (≥50 to ≤85 years of age) participants with Alzheimer's disease (AD) and mild-to-moderate cognitive impairment were enrolled at 4 study centers in the United States.

Participant flow — Overall Study
MilestoneMK-1942 ADPlacebo + Donepezil AD
Started225
Completed175
Not completed50
Withdrew: Withdrawal by subject40
Withdrew: Protocol violation10

Outcome measures

PrimaryNumber of Participants With ≥1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to Day 42
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Adverse Event (AE)
ParticipantsMK-1942 8 mg + Donepezil ADMK-1942 15 mg + Donepezil ADMK-1942 30 mg + Donepezil ADMK-1942 50 mg + Donepezil ADPlacebo + Donepezil AD
Number of Participants With ≥1 Adverse Event (AE)134454
PrimaryNumber of Participants Discontinuing From Study Therapy Due to an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants Discontinuing From Study Therapy Due to an Adverse Event (AE)
ParticipantsMK-1942 8 mg ADMK-1942 15 mg ADMK-1942 30 mg ADMK-1942 50 mg ADPlacebo AD
Number of Participants Discontinuing From Study Therapy Due to an Adverse Event (AE)00000
PrimaryNumber of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Findings

The number of participants with clinically significant 12-lead ECGs is presented. Recordings were made throughout the study, with the participant in a semi-recumbent position having rested in this position for at least 10 minutes beforehand.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Findings
ParticipantsMK-1942 8 mgMK-1942 15 mgMK-1942 30 mgMK-1942 50 mgPlacebo AD
Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Findings10001
PrimaryNumber of Participants With Abnormal (Impaired) Results on Targeted Neurological Exams

The number of participants with abnormal (impaired) results on targeted neurological exams will be presented. The targeted neurological exam contains Modules 1, 2 and 5 of the general examination, focusing on arousal, cranial nerve function, and gait and will be administered several times throughout the treatment period starting on Day 1 up until Day 29. The number of participants with abnormal (impaired) results on targeted neurological exams will be reported. Each exam will be graded as Normal or Impaired with the abnormality described.

Time frame:
Up to 29 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal (Impaired) Results on Targeted Neurological Exams
ParticipantsMK-1942 8 mgMK-1942 15 mgMK-1942 30 mgMK-1942 50 mgPlacebo AD
Number of Participants With Abnormal (Impaired) Results on Targeted Neurological Exams00000
PrimaryNumber of Participants Who Reported Suicidal Ideation and/or Behavior on Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS)

The number of participants with suicidality using the C-SSRS is presented. The C-SSR will be used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. C-SSRS assessment will be based upon a clinician's interpretation of the participant's responses to the C-SSRS questions, not by a numbered scale. Suicidal ideation and/or behaviors identified on the C-SSRS may not be considered an adverse event, based on the investigator's judgment. Participants who report at least one occurrence of suicidal behavior or suicidal ideation will be counted as having experienced suicidality. Suicidal behavior includes suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation include a wish to die or active suicidal thought with or without method, intent or plan.

Time frame:
Up to 42 days
Reported as:
Count of participants · Participants
Number of Participants Who Reported Suicidal Ideation and/or Behavior on Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsMK-1942 8 mgMK-1942 15 mgMK-1942 30 mgMK-1942 50 mgPlacebo AD
Number of Participants Who Reported Suicidal Ideation and/or Behavior on Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS)00000
PrimaryChange From Baseline in Heart Rate (HR)

The mean change from baseline in HR is presented. Change in HR was determined the first day of treatment with a new dose of MK-1942. A negative value indicates a decrease in HR relative to baseline, and a positive value indicates an increase.

Time frame:
Baseline (Day -1) and Days 1, 8, 15, and 22: 2 hours postdose
Reported as:
Mean · beats/min
Change From Baseline in Heart Rate (HR)
beats/minMK-1942 8 mgMK-1942 15 mgMK-1942 30 mgMK-1942 50 mgPlacebo AD
Change From Baseline in Heart Rate (HR)-2.27 ± 1.252.56 ± 1.656.14 ± 2.270.21 ± 2.81-4.53 ± 1.06
PrimaryChange From Baseline in Systolic Blood Pressure (SBP)

The mean change from baseline in SBP is presented. Change in SBP was determined the first day of treatment with a new dose of MK-1942. Negative values represent a decrease in SBP relative to baseline, and positive values represent an increase.

Time frame:
Baseline (Day -1) and Days 1, 8, 15, and 22: 2 hours postdose
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (SBP)
mmHgMK-1942 8 mgMK-1942 15 mgMK-1942 30 mgMK-1942 50 mgPlacebo AD
Change From Baseline in Systolic Blood Pressure (SBP)2.48 ± 2.08-0.15 ± 2.590.88 ± 2.091.45 ± 2.195.93 ± 4.00
PrimaryMean Change From Baseline in Diastolic Blood Pressure (DBP)

The mean change from baseline in DBP is presented. Change in DBP was determined the first day of treatment with a new dose of MK-1942. Negative values represent a decrease in DBP relative to baseline, and positive values represent an increase.

Time frame:
Baseline (Day -1) and Days 1, 8, 15, and 22: 2 hours postdose
Reported as:
Mean · mmHg
Mean Change From Baseline in Diastolic Blood Pressure (DBP)
mmHgMK-1942 8 mgMK-1942 15 mgMK-1942 30 mgMK-1942 50 mgPlacebo AD
Mean Change From Baseline in Diastolic Blood Pressure (DBP)-0.95 ± 0.930.56 ± 2.011.17 ± 1.510.10 ± 1.39-1.73 ± 3.36
PrimaryNumber of Participants With Abnormal Clinical Chemistry Test Results Reported as Adverse Events

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal chemistry-related AEs is reported.

Time frame:
Up to 42 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Chemistry Test Results Reported as Adverse Events
ParticipantsMK-1942 8 mgMK-1942 15 mgMK-1942 30 mgMK-1942 50 mgPlacebo AD
Number of Participants With Abnormal Clinical Chemistry Test Results Reported as Adverse Events10010
PrimaryNumber of Participants With Abnormal Clinical Hematology Test Results Reported as Adverse Events

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal hematology-related AEs is reported.

Time frame:
Up to 42 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Hematology Test Results Reported as Adverse Events
ParticipantsMK-1942 8 mgMK-1942 15 mgMK-1942 30 mgMK-1942 50 mgPlacebo AD
Number of Participants With Abnormal Clinical Hematology Test Results Reported as Adverse Events01000
PrimaryNumber of Participants With Abnormal Urinalysis Results Reported as Adverse Events

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with an abnormal urinalysis results AE is reported.

Time frame:
Up to 42 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Results Reported as Adverse Events
ParticipantsMK-1942 8 mgMK-1942 15 mgMK-1942 30 mgMK-1942 50 mgPlacebo AD
Number of Participants With Abnormal Urinalysis Results Reported as Adverse Events100000
SecondaryArea Under the Plasma Concentration-Time Curve (AUC) From Dosing to 12 Hours Postdose (AUC0-12) of MK-1942

AUC0-12 is reported for the first day of treatment of each MK-1942 dose.

Time frame:
Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Least squares mean · hr*nmol/L
Area Under the Plasma Concentration-Time Curve (AUC) From Dosing to 12 Hours Postdose (AUC0-12) of MK-1942
hr*nmol/LMK-1942 8 mg + Donepezil ADMK-1942 15 mg + Donepezil ADMK-1942 30 mg + Donepezil ADMK-1942 50 mg + Donepezil AD
Area Under the Plasma Concentration-Time Curve (AUC) From Dosing to 12 Hours Postdose (AUC0-12) of MK-19421760 (1390 to 2240)3580 (2860 to 4490)6650 (5330 to 8280)11600 (9110 to 14700)
Statistical analysis
  • MK-1942 8 mg + Donepezil AD · Geometric mean ratio (gmr): 0.69 · 90% CI 0.55 to 0.86
  • MK-1942 15 mg + Donepezil AD · Gmr: 0.66 · 95% CI 0.53 to 0.82
  • MK-1942 30 mg + Donepezil AD · Gmr: 0.74 · 95% CI 0.55 to 1.00
  • MK-1942 50 mg + Donepezil AD · Gmr: 0.77 · 95% CI 0.56 to 1.05
SecondaryAUC From Dosing to 24 Hours Postdose (AUC0-24) of MK-1942

AUC0-24 is reported for the first day of treatment of each MK-1942 dose. Due to twice daily dosing, AUC0-24 was calculated as "AUC0-24 = AUC0-12 x 2".

Time frame:
Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Least squares mean · hr*nmol/L
AUC From Dosing to 24 Hours Postdose (AUC0-24) of MK-1942
hr*nmol/LMK-1942 8 mg + Donepezil ADMK-1942 15 mg + Donepezil ADMK-1942 30 mg + Donepezil ADMK-1942 50 mg + Donepezil AD
AUC From Dosing to 24 Hours Postdose (AUC0-24) of MK-19423530 (2790 to 4470)7160 (5710 to 8970)13330 (10700 to 16600)23200 (18200 to 29500)
Statistical analysis
  • MK-1942 8 mg + Donepezil AD · Geometric mean ratio (gmr): 0.69 · 90% CI 0.55 to 0.86
  • MK-1942 15 mg + Donepezil AD · Gmr: 0.66 · 95% CI 0.53 to 0.82
  • MK-1942 30 mg + Donepezil AD · Gmr: 0.74 · 95% CI 0.55 to 1.00
  • MK-1942 50 mg + Donepezil AD · Gmr: 0.77 · 95% CI 0.56 to 1.05
SecondaryMaximum Plasma Concentration (Cmax) of MK-1942

Cmax is reported for the first day of treatment of each MK-1942 dose.

Time frame:
Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Least squares mean · nmol/L
Maximum Plasma Concentration (Cmax) of MK-1942
nmol/LMK-1942 8 mg + Donepezil ADMK-1942 15 mg + Donepezil ADMK-1942 30 mg + Donepezil ADMK-1942 50 mg + Donepezil AD
Maximum Plasma Concentration (Cmax) of MK-1942239 (184 to 310)477 (371 to 613)876 (731 to 1050)1360 (1080 to 1720)
Statistical analysis
  • MK-1942 8 mg + Donepezil AD · Geometric mean ratio (gmr): 0.67 · 90% CI 0.52 to 0.87
  • MK-1942 15 mg + Donepezil AD · Gmr: 0.68 · 95% CI 0.52 to 0.87
  • MK-1942 30 mg + Donepezil AD · Gmr: 0.79 · 95% CI 0.59 to 1.06
  • MK-1942 50 mg + Donepezil AD · Gmr: 0.74 · 95% CI 0.51 to 1.08
SecondaryTrough Plasma Concentration (Ctrough) of MK-1942

Ctrough is reported for the first day of treatment of each MK-1942 dose. Data from healthy elderly participants used for statistical analyses are unpublished findings from study MK-1942-004.

Time frame:
Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Least squares mean · nmol/L
Trough Plasma Concentration (Ctrough) of MK-1942
nmol/LMK-1942 8 mg + Donepezil ADMK-1942 15 mg + Donepezil ADMK-1942 30 mg + Donepezil ADMK-1942 50 mg + Donepezil AD
Trough Plasma Concentration (Ctrough) of MK-1942101 (79.7 to 127)228 (188 to 277)386 (282 to 527)693 (528 to 910)
Statistical analysis
  • MK-1942 8 mg + Donepezil AD · Geometric mean ratio (gmr): 0.62 · 90% CI 0.48 to 0.80
  • MK-1942 15 mg + Donepezil AD · Gmr: 0.67 · 95% CI 0.55 to 0.81
  • MK-1942 30 mg + Donepezil AD · Gmr: 0.68 · 95% CI 0.49 to 0.93
  • MK-1942 50 mg + Donepezil AD · Gmr: 0.72 · 95% CI 0.54 to 0.98
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of MK-1942

Tmax is reported for the first day of treatment of each MK-1942 dose.

Time frame:
Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Median · Hours
Time to Reach Maximum Plasma Concentration (Tmax) of MK-1942
HoursMK-1942 8 mg + Donepezil ADMK-1942 15 mg + Donepezil ADMK-1942 30 mg + Donepezil ADMK-1942 50 mg + Donepezil AD
Time to Reach Maximum Plasma Concentration (Tmax) of MK-19421.97 (0.93 to 3.00)1.98 (0.43 to 3.00)2.00 (1.00 to 5.95)2.00 (1.93 to 3.08)
SecondaryApparent Terminal Plasma Half-Life (t½) of MK-1942

t½ is reported for MK-1942 50 mg.

Time frame:
Day 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Geometric mean · Hours
Apparent Terminal Plasma Half-Life (t½) of MK-1942
HoursMK-1942 50 mg + Donepezil AD
Apparent Terminal Plasma Half-Life (t½) of MK-194226.7 ± 27.7
SecondaryApparent Clearance at Steady-state (CLss/F) of MK-1942

CLss/F is reported for MK-1942 50 mg.

Time frame:
Day 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Geometric mean · L/h
Apparent Clearance at Steady-state (CLss/F) of MK-1942
L/hMK-1942 50 mg + Donepezil AD
Apparent Clearance at Steady-state (CLss/F) of MK-194211.7 ± 45.5
SecondaryApparent Volume of Distribution at Steady State (Vzss/F) of MK-1942

Vzss/F is reported for MK-1942 50 mg.

Time frame:
Day 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution at Steady State (Vzss/F) of MK-1942
LitersMK-1942 50 mg + Donepezil AD
Apparent Volume of Distribution at Steady State (Vzss/F) of MK-1942449 ± 41.1
SecondaryAUC0-24 of Donepezil

AUC0-24 is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28). Due to twice daily dosing, AUC0-24 was calculated as "AUC0-12 x 2".

Time frame:
Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Geometric mean · hr*ng/mL
AUC0-24 of Donepezil
hr*ng/mLDonepezil Day -1Donepezil Day 28
AUC0-24 of Donepezil606 ± 66.4919 ± 44.4
Statistical analysis
  • Donepezil Day -1 vs Donepezil Day 28 · Geometric mean: 1.34
SecondaryCmax of Donepezil

Cmax is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).

Time frame:
Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Geometric mean · ng/mL
Cmax of Donepezil
ng/mLDonepezil Day -1Donepezil Day 28
Cmax of Donepezil37.9 ± 56.453.3 ± 42.2
Statistical analysis
  • Donepezil Day -1 vs Donepezil Day 28 · Geometric mean: 1.22
SecondaryCtrough of Donepezil

Ctrough is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).

Time frame:
Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Geometric mean · ng/mL
Ctrough of Donepezil
ng/mLDonepezil Day -1Donepezil Day 28
Ctrough of Donepezil20.1 ± 72.731.8 ± 52.5
Statistical analysis
  • Donepezil Day -1 vs Donepezil Day 28 · Geometric mean: 1.46
SecondaryTmax of Donepezil

Tmax is reported for donepezil 10 mg alone (Day -1) or with MK-1942 50 mg (Day 28).

Time frame:
Days 1, 7, 14, and 21 (morning dose only): predose and 0.5, 1, 2, 3, 4, 6, and 12 hours postdose
Reported as:
Median · Hours
Tmax of Donepezil
HoursDonepezil Day -1Donepezil Day 28
Tmax of Donepezil2.05 (0.00 to 4.00)2.03 (1.00 to 3.95)

Adverse events

Collected over Up to 42 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-1942 8 mg BID 7 Days0/22 (0%)0/22 (0%)13/22 (59.1%)
MK-1942 15 mg BID 7 Days0/19 (0%)0/19 (0%)4/19 (21.1%)
MK-1942 30 mg Bid 7D0/15 (0%)0/15 (0%)4/15 (26.7%)
MK-1942 50 mg BID & Days0/15 (0%)0/15 (0%)5/15 (33.3%)
MK-1942 Total0/22 (0%)0/22 (0%)18/22 (81.8%)
Placebo Bid0/5 (0%)0/5 (0%)4/5 (80%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventMK-1942 8 mg BID 7 DaysMK-1942 15 mg BID 7 DaysMK-1942 30 mg Bid 7DMK-1942 50 mg BID & DaysMK-1942 TotalPlacebo Bid
NauseaGastrointestinal disorders5/221/190/152/157/222/5
HeadacheNervous system disorders1/220/190/150/151/222/5
DizzinessNervous system disorders3/220/192/150/155/221/5
Scleral hyperaemiaEye disorders0/220/190/150/150/221/5
Vision blurredEye disorders1/220/190/150/151/221/5
Gait disturbanceGeneral disorders0/220/190/150/150/221/5
Oedema peripheralGeneral disorders0/220/190/150/150/221/5
Vessel puncture site bruiseGeneral disorders0/220/190/150/150/221/5
Upper respiratory tract infectionInfections and infestations0/220/190/150/150/221/5
Electrocardiogram T wave biphasicInvestigations0/220/190/150/150/221/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)MK-1942 ADPlacebo + Donepezil ADTotal
Mean69.1 ± 5.569.4 ± 2.669.2 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)MK-1942 ADPlacebo + Donepezil ADTotal
Female10212
Male12315
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-1942 ADPlacebo + Donepezil ADTotal
Hispanic or Latino19423
Not Hispanic or Latino213
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-1942 ADPlacebo + Donepezil ADTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American707
White15520
More than one race000
Unknown or Not Reported000
08

Study locations

4 sites
  • Woodland Research Northwest, LLC ( Site 0004)
    Rogers, Arkansas 72758-6442, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 0002)
    Hallandale Beach, Florida 33009, United States
  • iResearch Atlanta ( Site 0005)
    Decatur, Georgia 30030, United States
  • ICON ( Site 0003)
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2022, 15 months.

Results were first posted in Aug 2024, 2 years 2 months after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 15 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2020
First posted
Mar 16, 2020
StartActual
Feb 16, 2021
Primary completionActual
May 18, 2022
CompletionActual
May 18, 2022
Results first posted
Aug 15, 2024
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04308304
Responsible party
Sponsor
First posted
Mar 16, 2020
Start date
Feb 16, 2021
Primary completion
May 18, 2022
Completion
May 18, 2022
Results posted
Aug 15, 2024
Last update
Aug 15, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MK-1942 · Donepezil

Start the discussion